The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
P53 as a predictor of clinical outcome in localized prostate cancer.
 
Kate Lynette Mahon
Travel, Accommodations, Expenses - Astellas Oncology
 
Phillip Stricker
No Relationships to Disclose
 
James Kench
No Relationships to Disclose
 
Judith Grogan
No Relationships to Disclose
 
Warick Delprado
No Relationships to Disclose
 
Jenny Turner
No Relationships to Disclose
 
Lisa Horvath
Consulting or Advisory Role - Astellas Oncology
Research Funding - Astellas Oncology (Inst)
Travel, Accommodations, Expenses - Astellas Oncology; Janssen-Cilag
 
David I. Quinn
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)